{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:15:03Z","timestamp":1793931303985,"version":"4.8.0"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007613","name":"Ankara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Nutr Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Obesity pharmacotherapy has become increasingly relevant in older adults due to challenges in lifestyle modification and the burden of non-communicable diseases. Despite the expanding use of anti-obesity medications (AOMs), sarcopenia and sarcopenic obesity (SO) remain major concerns in this population. This review synthesizes current evidence on glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a well-studied AOMs, focusing on their effects on sarcopenia through mechanistic insights and clinical considerations in older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>GLP-1 RAs effectively induce weight loss; however, concomitant muscle mass loss is common, raising concerns about sarcopenia. Weight cycling introduces uncertainty regarding skeletal muscle health and SO risk. Although data on muscle mass indices and physical performance remain limited and inconsistent, evidence suggests favorable effects on muscle metabolism and composition. Mechanistically, these effects are linked to GLP-1 RA-mediated suppression of inflammatory pathways, modulation of skeletal muscle metabolism, and preservation of mitochondrial function, thereby influencing insulin resistance. The most common adverse events are mild to moderate gastrointestinal symptoms, which may be mitigated through dietary counseling during dose escalation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Integrating GLP-1 RA therapy with tailored resistance exercise and caloric restriction with dietary counseling, including adequate protein intake (1.2\u20131.6\u00a0g\/kg\/day), may help preserve muscle mass and function in older adults. Implementation of GLP-1 RA-specific medical nutrition therapy protocols, with dietitian involvement to optimize dietary recommendations and manage adverse events, is recommended. Studies addressing skeletal muscle quantity, quality, and functional capacity are needed to clarify the effects of GLP-1 RAs on sarcopenic obesity in older adults.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s13668-026-00777-x","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:53:02Z","timestamp":1781661182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2744-1610","authenticated-orcid":false,"given":"Hilal","family":"Simsek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9724-9571","authenticated-orcid":false,"given":"Asli","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"10481","key":"777_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"M Ng","year":"1990","unstructured":"Ng M, et al. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 1990;405(10481):813\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(25)00355-1.","journal-title":"Lancet"},{"issue":"3","key":"777_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","volume":"15","author":"LM Donini","year":"2022","unstructured":"Donini LM, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15(3):321\u201335. https:\/\/doi.org\/10.1159\/000521241.","journal-title":"Obes Facts"},{"issue":"7","key":"777_CR3","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1016\/j.clnu.2021.06.009","volume":"40","author":"Q Gao","year":"2021","unstructured":"Gao Q, et al. Global prevalence of sarcopenic obesity in older adults: a systematic review and meta-analysis. Clin Nutr. 2021;40(7):4633\u201341. https:\/\/doi.org\/10.1016\/j.clnu.2021.06.009.","journal-title":"Clin Nutr"},{"key":"777_CR4","doi-asserted-by":"publisher","first-page":"e240084","DOI":"10.20945\/2359-4292-2024-0084","volume":"68","author":"VZC Borba","year":"2025","unstructured":"Borba VZC, Costa T. Sarcopenic obesity: a review. Arch Endocrinol Metab. 2025;68:e240084. https:\/\/doi.org\/10.20945\/2359-4292-2024-0084.","journal-title":"Arch Endocrinol Metab"},{"key":"777_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.maturitas.2018.11.003","volume":"119","author":"O Bruy\u00e8re","year":"2019","unstructured":"Bruy\u00e8re O, et al. The health economics burden of sarcopenia: a systematic review. Maturitas. 2019;119:61\u20139. https:\/\/doi.org\/10.1016\/j.maturitas.2018.11.003.","journal-title":"Maturitas"},{"issue":"3","key":"777_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000542821","volume":"18","author":"E Oksuz","year":"2025","unstructured":"Oksuz E, et al. Annual health expenditures by body mass index categories and the economic impact of obesity in T\u00fcrkiye: a retrospective modeling study. Obes Facts. 2025;18(3):269\u201386. https:\/\/doi.org\/10.1159\/000542821.","journal-title":"Obes Facts"},{"issue":"1","key":"777_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1532-5415.2004.52014.x","volume":"52","author":"I Janssen","year":"2004","unstructured":"Janssen I, et al. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80\u20135. https:\/\/doi.org\/10.1111\/j.1532-5415.2004.52014.x.","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"777_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.14283\/jfa.2019.10","volume":"8","author":"S Goates","year":"2019","unstructured":"Goates S, et al. Economic impact of hospitalizations in US adults with sarcopenia. J Frailty Aging. 2019;8(2):93\u20139. https:\/\/doi.org\/10.14283\/jfa.2019.10.","journal-title":"J Frailty Aging"},{"issue":"1","key":"777_CR9","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1186\/s12889-022-13176-y","volume":"22","author":"E van den Broek-Altenburg","year":"2022","unstructured":"van den Broek-Altenburg E, Atherly A, Holladay E. Changes in healthcare spending attributable to obesity and overweight: payer- and service-specific estimates. BMC Public Health. 2022;22(1):962. https:\/\/doi.org\/10.1186\/s12889-022-13176-y.","journal-title":"BMC Public Health"},{"key":"777_CR10","doi-asserted-by":"publisher","first-page":"1185221","DOI":"10.3389\/fendo.2023.1185221","volume":"14","author":"S Wei","year":"2023","unstructured":"Wei S, et al. Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management. Front Endocrinol (Lausanne). 2023;14:1185221. https:\/\/doi.org\/10.3389\/fendo.2023.1185221.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"777_CR11","doi-asserted-by":"publisher","first-page":"1253267","DOI":"10.3389\/fpubh.2023.1253267","volume":"11","author":"PJ van der Laag","year":"2023","unstructured":"van der Laag PJ, et al. Barriers and facilitators for implementation of a combined lifestyle intervention in community-dwelling older adults: a scoping review. Front Public Health. 2023;11:1253267. https:\/\/doi.org\/10.3389\/fpubh.2023.1253267.","journal-title":"Front Public Health"},{"issue":"11","key":"777_CR12","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40266-024-01150-9","volume":"41","author":"O \u017di\u017eka","year":"2024","unstructured":"\u017di\u017eka O, Haluz\u00edk M, Jude EB. Pharmacological treatment of obesity in older adults. Drugs Aging. 2024;41(11):881\u201396. https:\/\/doi.org\/10.1007\/s40266-024-01150-9.","journal-title":"Drugs Aging"},{"key":"777_CR13","doi-asserted-by":"crossref","unstructured":"Sames C. Chapter 3 - age-related physiological changes: an overview. In: Avers D, Wong RA, editors. Guccione\u2019s Geriatric Physical Therapy (Fourth Edition). St. Louis (MO): Mosby; 2020. p. 38\u201354.","DOI":"10.1016\/B978-0-323-60912-8.00003-8"},{"issue":"4","key":"777_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/mco.0000000000001131","volume":"28","author":"A Caturano","year":"2025","unstructured":"Caturano A, et al. Sarcopenic obesity and weight loss-induced muscle mass loss. Curr Opin Clin Nutr Metab Care. 2025;28(4):339\u201350. https:\/\/doi.org\/10.1097\/mco.0000000000001131.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"5","key":"777_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-023-00943-z","volume":"20","author":"CM Prado","year":"2024","unstructured":"Prado CM, et al. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol. 2024;20(5):261\u201377. https:\/\/doi.org\/10.1038\/s41574-023-00943-z.","journal-title":"Nat Rev Endocrinol"},{"key":"777_CR16","doi-asserted-by":"publisher","unstructured":"Hong SH, Choi KM. Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences. Int J Mol Sci, 2020; 21(2).https:\/\/doi.org\/10.3390\/ijms21020494","DOI":"10.3390\/ijms21020494"},{"issue":"20","key":"777_CR17","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, et al. Obesity management in adults: a review. Jama. 2023;330(20):2000\u201315. https:\/\/doi.org\/10.1001\/jama.2023.19897.","journal-title":"Jama"},{"issue":"6","key":"777_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1159\/000442721","volume":"8","author":"V Yumuk","year":"2015","unstructured":"Yumuk V, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402\u201324. https:\/\/doi.org\/10.1159\/000442721.","journal-title":"Obes Facts"},{"issue":"15 Suppl","key":"777_CR19","doi-asserted-by":"publisher","first-page":"S288","DOI":"10.37765\/ajmc.2022.89292","volume":"28","author":"MA Cornier","year":"2022","unstructured":"Cornier MA. A review of current guidelines for the treatment of obesity. Am J Manag Care. 2022;28(15 Suppl):S288-s296. https:\/\/doi.org\/10.37765\/ajmc.2022.89292.","journal-title":"Am J Manag Care"},{"issue":"1","key":"777_CR20","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1186\/s12877-024-05157-0","volume":"24","author":"Y-H Yin","year":"2024","unstructured":"Yin Y-H, Liu JYW, V\u00e4lim\u00e4ki M. \u201cHow difficult it is to change dietary behaviour\u201d experience of older people with sarcopenic obesity: a qualitative study. BMC Geriatrics. 2024;24(1):568. https:\/\/doi.org\/10.1186\/s12877-024-05157-0.","journal-title":"BMC Geriatrics"},{"issue":"4","key":"777_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/apt.17856","volume":"59","author":"C Lupianez-Merly","year":"2024","unstructured":"Lupianez-Merly C, et al. Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks. Aliment Pharmacol Ther. 2024;59(4):475\u201391. https:\/\/doi.org\/10.1111\/apt.17856.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"777_CR22","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, et al. A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med. 2025;31(10):3317\u201329. https:\/\/doi.org\/10.1038\/s41591-025-03978-z.","journal-title":"Nat Med"},{"key":"777_CR23","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"issue":"8","key":"777_CR24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24(8):631\u201350. https:\/\/doi.org\/10.1038\/s41573-025-01183-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"777_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3390\/pharmaceutics17081036","volume":"17","author":"S Patel","year":"2025","unstructured":"Patel S, Niazi SK. Emerging frontiers in GLP-1 therapeutics: a comprehensive evidence base (2025). Pharmaceutics. 2025;17(8):1036.","journal-title":"Pharmaceutics"},{"key":"777_CR26","doi-asserted-by":"publisher","first-page":"7128859","DOI":"10.1155\/2022\/7128859","volume":"2022","author":"J Zhang","year":"2022","unstructured":"Zhang J, et al. Efficacy of exenatide administered twice daily in body mass index reduction in patients with type 2 diabetes mellitus. Int J Clin Pract. 2022;2022:7128859. https:\/\/doi.org\/10.1155\/2022\/7128859.","journal-title":"Int J Clin Pract"},{"key":"777_CR27","unstructured":"FDA. Byetta (Exenatide). 2009 24.05.26]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021773s9s11s18s22s25lbl.pdf.\u00a0Accessed 24\u00a0May 2026."},{"key":"777_CR28","unstructured":"EMA. Byetta (exenatide). 2012; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/byetta-epar-summary-public_en.pdf.\u00a0Accessed 10 Nov 2025."},{"key":"777_CR29","unstructured":"FDA. Saxenda (Liraglutide). 2014; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321orig1s000lbl.pdf. Accessed 16 Nov 2025."},{"key":"777_CR30","unstructured":"EMA. Saxenda\u2014summary of product characteristics. 2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/saxenda-epar-product-information_en.pdf. Accessed 10 Nov 2025."},{"key":"777_CR31","unstructured":"EMA. Ozempic (semaglutide). 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/ozempic-epar-summary-public_en.pdf.\u00a0Accessed 16 Nov 2025."},{"key":"777_CR32","unstructured":"EMA. Rybelsus (semaglutide). 2020. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rybelsus.\u00a0Accessed 16 Nov 2025."},{"key":"777_CR33","unstructured":"Kommu S, W. P. Semaglutide, in StatPearls [Internet]. 2024, Treasure Island (FL): StatPearls Publishing."},{"key":"777_CR34","unstructured":"Farzam K, P. P. Tirzepatide, in StatPearls [Internet]. 2024."},{"key":"777_CR35","unstructured":"EMA. Mounjaro. Tirzepatide. 2023. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-mounjaro-ii-07_en.pdf. Accessed 11 Nov 2025"},{"key":"777_CR36","unstructured":"FDA. Mounjaro (Tirzepatide). 2022. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. Accessed 11 Nov 2025"},{"issue":"6","key":"777_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0091270006288215","volume":"46","author":"B Damholt","year":"2006","unstructured":"Damholt B, et al. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006;46(6):635\u201341. https:\/\/doi.org\/10.1177\/0091270006288215.","journal-title":"J Clin Pharmacol"},{"key":"777_CR38","unstructured":"Cerillo JL, P. M. Liraglutide. In: StatPearls [Internet]. 2024, Treasure Island (FL): StatPearls Publishing."},{"key":"777_CR39","doi-asserted-by":"publisher","first-page":"107927","DOI":"10.1016\/j.phrs.2025.107927","volume":"220","author":"A Ceasovschih","year":"2025","unstructured":"Ceasovschih A, et al. Glucagon-like peptide-1 receptor agonists and muscle mass effects. Pharmacol Res. 2025;220:107927. https:\/\/doi.org\/10.1016\/j.phrs.2025.107927.","journal-title":"Pharmacol Res"},{"key":"777_CR40","doi-asserted-by":"publisher","first-page":"152822","DOI":"10.1016\/j.bbrc.2025.152822","volume":"789","author":"MA Ngabea","year":"2025","unstructured":"Ngabea MA, Dimeji IY. GLP-1 receptor agonists and inflammatory pathway modulation: Dual targeting of metabolic and immune dysfunction in insulin resistance. Biochem Biophys Res Commun. 2025;789:152822. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152822.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"777_CR41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892.","journal-title":"N Engl J Med"},{"issue":"7","key":"777_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. Jama. 2015;314(7):687\u201399. https:\/\/doi.org\/10.1001\/jama.2015.9676.","journal-title":"Jama"},{"key":"777_CR43","doi-asserted-by":"crossref","unstructured":"Rubino D. et al. Age no impediment to effective weight loss with liraglutide 3.0 mg: data from two randomized trials. Int. J. Nutrol. 2018; 11","DOI":"10.1055\/s-0038-1674366"},{"issue":"16","key":"777_CR44","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000042155","volume":"104","author":"A Oral","year":"2025","unstructured":"Oral A, K\u00fc\u00e7\u00fck C, Kayalar Y. Is liraglutide safe and effective in the elderly obese patients?: a single center experience. Medicine (Baltimore). 2025;104(16):e42155. https:\/\/doi.org\/10.1097\/md.0000000000042155.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"777_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.14740\/jocmr3647","volume":"11","author":"S Ishii","year":"2019","unstructured":"Ishii S, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series. J Clin Med Res. 2019;11(3):219\u201324. https:\/\/doi.org\/10.14740\/jocmr3647.","journal-title":"J Clin Med Res"},{"issue":"2","key":"777_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","volume":"118","author":"KE Elkind-Hirsch","year":"2022","unstructured":"Elkind-Hirsch KE, et al. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil Steril. 2022;118(2):371\u201381. https:\/\/doi.org\/10.1016\/j.fertnstert.2022.04.027.","journal-title":"Fertil Steril"},{"issue":"1","key":"777_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/oby.23596","volume":"31","author":"S Santini","year":"2023","unstructured":"Santini S, et al. Marked weight loss on liraglutide 3.0 mg: Real-life experience of a Swiss cohort with obesity. Obesity (Silver Spring). 2023;31(1):74\u201382. https:\/\/doi.org\/10.1002\/oby.23596.","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"777_CR48","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/jcsm.13445","volume":"15","author":"A Pandey","year":"2024","unstructured":"Pandey A, et al. Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial. J Cachexia Sarcopenia Muscle. 2024;15(3):1072\u201383. https:\/\/doi.org\/10.1002\/jcsm.13445.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"777_CR49","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.orcp.2025.01.009","volume":"19","author":"PHS Schmidt","year":"2025","unstructured":"Schmidt PHS, et al. Effects of liraglutide on body composition in people living with obesity or overweight: A systematic review. Obes Res Clin Pract. 2025;19(1):11\u20138. https:\/\/doi.org\/10.1016\/j.orcp.2025.01.009.","journal-title":"Obes Res Clin Pract"},{"issue":"6","key":"777_CR50","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","volume":"28","author":"S Perna","year":"2016","unstructured":"Perna S, et al. Liraglutide and obesity in elderly: efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study. Aging Clin Exp Res. 2016;28(6):1251\u20137. https:\/\/doi.org\/10.1007\/s40520-015-0525-y.","journal-title":"Aging Clin Exp Res"},{"key":"777_CR51","unstructured":"Warren M. et al. Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1\u20135 trials. In: Diabetologia. Springer, New York, NY 10013 USA; 2017."},{"issue":"1","key":"777_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/87551225221137493","volume":"39","author":"G Huynh","year":"2023","unstructured":"Huynh G, Runeberg H, Weideman R. Evaluating weight loss with semaglutide in elderly patients with type II diabetes. J Pharm Technol. 2023;39(1):10\u20135. https:\/\/doi.org\/10.1177\/87551225221137493.","journal-title":"J Pharm Technol"},{"issue":"11","key":"777_CR53","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"issue":"2","key":"777_CR54","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. Jama. 2022;327(2):138\u201350. https:\/\/doi.org\/10.1001\/jama.2021.23619.","journal-title":"Jama"},{"issue":"9","key":"777_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/medicines9090047","volume":"9","author":"Y Ozeki","year":"2022","unstructured":"Ozeki Y, et al. The effectiveness of GLP-1 receptor agonist semaglutide on body composition in elderly obese diabetic patients: a pilot study. Medicines. 2022;9(9):47.","journal-title":"Medicines"},{"issue":"12","key":"777_CR56","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.3390\/nu14122414","volume":"14","author":"S Volpe","year":"2022","unstructured":"Volpe S, et al. Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: a 26-week prospective real-life study. Nutrients. 2022;14(12):2414.","journal-title":"Nutrients"},{"issue":"2","key":"777_CR57","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/dom.14571","volume":"24","author":"Y Yamada","year":"2022","unstructured":"Yamada Y, et al. Efficacy and safety of oral semaglutide by baseline age in Japanese patients with type 2 diabetes: a subgroup analysis of the PIONEER 9 and 10 Japan trials. Diabetes Obes Metab. 2022;24(2):321\u20136. https:\/\/doi.org\/10.1111\/dom.14571.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"777_CR58","doi-asserted-by":"publisher","first-page":"377","DOI":"10.14740\/jocmr4987","volume":"15","author":"S Uchiyama","year":"2023","unstructured":"Uchiyama S, et al. Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes. J Clin Med Res. 2023;15(7):377\u201383. https:\/\/doi.org\/10.14740\/jocmr4987.","journal-title":"J Clin Med Res"},{"issue":"4","key":"777_CR59","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/dom.16174","volume":"27","author":"V Fiore","year":"2025","unstructured":"Fiore V, et al. Real\u2010world retrospective study in elderly patients aged 65\u2009years and older with type 2 diabetes mellitus treated with daily oral semaglutide (<scp>SEMA<\/scp>\u2010elderly). Diabetes Obes Metab. 2025;27(4):1805\u201314. https:\/\/doi.org\/10.1111\/dom.16174.","journal-title":"Diabetes Obes Metab"},{"key":"777_CR60","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.2147\/dddt.S531778","volume":"19","author":"Q Ren","year":"2025","unstructured":"Ren Q, Zhi L, Liu H. Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: A 24-month retrospective cohort study. Drug Des Devel Ther. 2025;19:5645\u201352. https:\/\/doi.org\/10.2147\/dddt.S531778.","journal-title":"Drug Des Devel Ther"},{"key":"777_CR61","doi-asserted-by":"publisher","DOI":"10.2196\/62667","volume":"13","author":"TM Cortes","year":"2024","unstructured":"Cortes TM, et al. Effect of semaglutide on physical function, body composition, and biomarkers of aging in older adults with overweight and insulin resistance: protocol for an open-labeled randomized controlled trial. JMIR Res Protoc. 2024;13:e62667. https:\/\/doi.org\/10.2196\/62667.","journal-title":"JMIR Res Protoc"},{"issue":"6","key":"777_CR62","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345. https:\/\/doi.org\/10.1001\/jama.2022.0078.","journal-title":"JAMA"},{"issue":"10295","key":"777_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(21)01324-6.","journal-title":"Lancet"},{"issue":"2","key":"777_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/jod.jod_16_23","volume":"14","author":"MA Abdalla","year":"2023","unstructured":"Abdalla MA, et al. Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: a pooled analysis of subgroups of SURPASS 1\u20135 trials. J Diabetol. 2023;14(2):65\u201373.","journal-title":"J Diabetol"},{"issue":"6","key":"777_CR65","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/s2213-8587(25)00027-0","volume":"13","author":"N Sattar","year":"2025","unstructured":"Sattar N, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(6):482\u201393. https:\/\/doi.org\/10.1016\/s2213-8587(25)00027-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"777_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"777_CR67","unstructured":"Arrone LJ et al. New analysis shows improved body composition with tirzepatide is consistent across adult age groups with overweight or obesity. ECO2023 Newsletter; 2023."},{"issue":"5","key":"777_CR68","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/dom.16275","volume":"27","author":"M Look","year":"2025","unstructured":"Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720\u20139. https:\/\/doi.org\/10.1111\/dom.16275.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"777_CR69","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89020","volume":"17","author":"RA Hidalgo Ramos","year":"2025","unstructured":"Hidalgo Ramos RA, et al. Effects of tirzepatide on skeletal muscle mass in adults: a systematic review. Cureus. 2025;17(7):e89020. https:\/\/doi.org\/10.7759\/cureus.89020.","journal-title":"Cureus"},{"key":"777_CR70","doi-asserted-by":"publisher","DOI":"10.1177\/2040622319862691","volume":"10","author":"OF Onoviran","year":"2019","unstructured":"Onoviran OF, et al. Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. Ther Adv Chronic Dis. 2019;10:2040622319862691. https:\/\/doi.org\/10.1177\/2040622319862691.","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"777_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3810\/pgm.2012.07.2567","volume":"124","author":"R Pencek","year":"2012","unstructured":"Pencek R, et al. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124(4):21\u201332. https:\/\/doi.org\/10.3810\/pgm.2012.07.2567.","journal-title":"Postgrad Med"},{"issue":"6","key":"777_CR72","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1185\/03007995.2012.686901","volume":"28","author":"M Pawaskar","year":"2012","unstructured":"Pawaskar M, Li Q, Reynolds MW. Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting. Curr Med Res Opin. 2012;28(6):991\u20137. https:\/\/doi.org\/10.1185\/03007995.2012.686901.","journal-title":"Curr Med Res Opin"},{"key":"777_CR73","doi-asserted-by":"publisher","unstructured":"Su N, Sun X, et al. Exenatide in obese or overweight patients without diabetes: a systematic review and meta-analyses of randomized controlled trials. Int J Cardiol. 2016;219:293\u2013300. https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.028.","DOI":"10.1016\/j.ijcard.2016.06.028"},{"key":"777_CR74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12986-018-0295-6","volume":"15","author":"TT Yin","year":"2018","unstructured":"Yin TT, et al. Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. Nutr Metab (Lond). 2018;15:67. https:\/\/doi.org\/10.1186\/s12986-018-0295-6.","journal-title":"Nutr Metab (Lond)"},{"issue":"3","key":"777_CR75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41366-024-01529-z","volume":"49","author":"AE Henney","year":"2025","unstructured":"Henney AE, et al. Obesity pharmacotherapy in older adults: a narrative review of evidence. Int J Obes. 2025;49(3):369\u201380. https:\/\/doi.org\/10.1038\/s41366-024-01529-z.","journal-title":"Int J Obes"},{"issue":"4","key":"777_CR76","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/dom.14952","volume":"25","author":"A Kiyosue","year":"2023","unstructured":"Kiyosue A, et al. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes Obes Metab. 2023;25(4):1056\u201367. https:\/\/doi.org\/10.1111\/dom.14952.","journal-title":"Diabetes Obes Metab"},{"key":"777_CR77","doi-asserted-by":"publisher","unstructured":"Karakasis P et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metab - Clin Exp. 2025; 164. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113","DOI":"10.1016\/j.metabol.2024.156113"},{"issue":"6","key":"777_CR78","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/dom.15557","volume":"26","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. The effect of glucagon-like peptide-1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta-analysis. Diabetes Obes Metab. 2024;26(6):2401\u201311. https:\/\/doi.org\/10.1111\/dom.15557.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"777_CR79","doi-asserted-by":"publisher","first-page":"109221","DOI":"10.1016\/j.isci.2024.109221","volume":"27","author":"L Wang","year":"2024","unstructured":"Wang L, Valencak TG, Shan T. Fat infiltration in skeletal muscle: Influential triggers and regulatory mechanism. iScience. 2024;27(3):109221. https:\/\/doi.org\/10.1016\/j.isci.2024.109221.","journal-title":"iScience"},{"issue":"109","key":"777_CR80","doi-asserted-by":"publisher","first-page":"20150365","DOI":"10.1098\/rsif.2015.0365","volume":"12","author":"H Rahemi","year":"2015","unstructured":"Rahemi H, Nigam N, Wakeling JM. The effect of intramuscular fat on skeletal muscle mechanics: implications for the elderly and obese. J R Soc Interface. 2015;12(109):20150365. https:\/\/doi.org\/10.1098\/rsif.2015.0365.","journal-title":"J R Soc Interface"},{"issue":"9","key":"777_CR81","doi-asserted-by":"publisher","first-page":"e16042","DOI":"10.14814\/phy2.16042","volume":"12","author":"K Dondero","year":"2024","unstructured":"Dondero K, et al. The effects of myosteatosis on skeletal muscle function in older adults. Physiol Rep. 2024;12(9):e16042. https:\/\/doi.org\/10.14814\/phy2.16042.","journal-title":"Physiol Rep"},{"issue":"1","key":"777_CR82","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"777_CR83","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12178-025-09978-3","volume":"18","author":"A Gatto","year":"2025","unstructured":"Gatto A, et al. The effects of GLP-1 agonists on musculoskeletal health and orthopedic care. Curr Rev Musculoskelet Med. 2025;18(10):469\u201380. https:\/\/doi.org\/10.1007\/s12178-025-09978-3.","journal-title":"Curr Rev Musculoskelet Med"},{"key":"777_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-025-02611-2","author":"Gea Rossi","year":"2025","unstructured":"Rossi Gea, et al. Muscle loss and GLP-1R agonists use. Acta Diabetol. 2025. https:\/\/doi.org\/10.1007\/s00592-025-02611-2.","journal-title":"Acta Diabetol"},{"key":"777_CR85","unstructured":"Sattar N et al. Tirzepatide reduces muscle fat infiltration relative to insulin deglucec in people with type 2 diabetes (SURPASS-3 MRI). 2023. Available from: https:\/\/www.easd.org\/media-centre\/.\u00a0Accessed 11 Nov 2025."},{"key":"777_CR86","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038444","author":"T Kakegawa","year":"2024","unstructured":"Kakegawa T, et al. Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: a prospective cohort study. Medicine (Baltimore). 2024. https:\/\/doi.org\/10.1097\/MD.0000000000038444.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"777_CR87","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/cid\/ciae384","volume":"80","author":"GL Ditzenberger","year":"2024","unstructured":"Ditzenberger GL, et al. Effects of semaglutide on muscle structure and function in the SLIM LIVER study. Clin Infect Dis. 2024;80(2):389\u201396. https:\/\/doi.org\/10.1093\/cid\/ciae384.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"777_CR88","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/jcsm.13524","volume":"15","author":"HH Huang","year":"2024","unstructured":"Huang HH, Huang H\u2010H, et al. Sarcopenia-related changes in serum GLP-1 level affect myogenic differentiation. J Cachexia Sarcopenia Muscle. 2024;15(5):1708\u201321. https:\/\/doi.org\/10.1002\/jcsm.13524.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"777_CR89","doi-asserted-by":"publisher","first-page":"117","DOI":"10.26402\/jpp.2018.1.13","volume":"69","author":"AI Mazur-Bialy","year":"2018","unstructured":"Mazur-Bialy AI, et al. Myokine irisin-induced protection against oxidative stress in vitro. Involvement of heme oxygenase-1 and antioxidazing enzymes superoxide dismutase-2 and glutathione peroxidase. J Physiol Pharmacol. 2018;69(1):117\u201325. https:\/\/doi.org\/10.26402\/jpp.2018.1.13.","journal-title":"J Physiol Pharmacol"},{"key":"777_CR90","unstructured":"Li Z et al. The role of PANDER and its interplay with IL-6 in the regulation of GLP-1 secretion. Endocrine Connections, 2024; 13(11)"},{"key":"777_CR91","doi-asserted-by":"publisher","first-page":"204201882312223","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222370. https:\/\/doi.org\/10.1177\/20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"777_CR92","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/dmso.S425642","volume":"16","author":"J Xiang","year":"2023","unstructured":"Xiang J, et al. GLP-1RA liraglutide and semaglutide improves obesity-induced muscle atrophy via SIRT1 pathway. Diabetes Metab Syndr Obes. 2023;16:2433\u201346. https:\/\/doi.org\/10.2147\/dmso.S425642.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"777_CR93","doi-asserted-by":"publisher","first-page":"9926462","DOI":"10.1155\/2023\/9926462","volume":"2023","author":"F Deng","year":"2023","unstructured":"Deng F, et al. Dulaglutide protects mice against diabetic sarcopenia-mediated muscle injury by inhibiting inflammation and regulating the differentiation of myoblasts. Int J Endocrinol. 2023;2023:9926462. https:\/\/doi.org\/10.1155\/2023\/9926462.","journal-title":"Int J Endocrinol"},{"issue":"4","key":"777_CR94","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jcsm.12434","volume":"10","author":"Y Hong","year":"2019","unstructured":"Hong Y, et al. Amelioration of muscle wasting by glucagon-like peptide-1 receptor agonist in muscle atrophy. J Cachexia Sarcopenia Muscle. 2019;10(4):903\u201318. https:\/\/doi.org\/10.1002\/jcsm.12434.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"777_CR95","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","volume":"134","author":"S Wharton","year":"2022","unstructured":"Wharton S, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134(1):14\u20139. https:\/\/doi.org\/10.1080\/00325481.2021.2002616.","journal-title":"Postgrad Med"},{"issue":"16","key":"777_CR96","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","volume":"150","author":"J Linge","year":"2024","unstructured":"Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150(16):1288\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.067676.","journal-title":"Circulation"},{"issue":"Suppl 4","key":"777_CR97","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.15728","volume":"26","author":"IJ Neeland","year":"2024","unstructured":"Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26(Suppl 4):16\u201327. https:\/\/doi.org\/10.1111\/dom.15728.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"777_CR98","doi-asserted-by":"publisher","first-page":"100652","DOI":"10.1016\/j.jnha.2025.100652","volume":"29","author":"K Prokopidis","year":"2025","unstructured":"Prokopidis K, Daly RM, Suetta C. Weighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity? J Nutr Health Aging. 2025;29(10):100652. https:\/\/doi.org\/10.1016\/j.jnha.2025.100652.","journal-title":"J Nutr Health Aging"},{"issue":"7","key":"777_CR99","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/oby.22493","volume":"27","author":"AP Rossi","year":"2019","unstructured":"Rossi AP, et al. Weight cycling as a risk factor for low muscle mass and strength in a population of males and females with obesity. Obesity (Silver Spring). 2019;27(7):1068\u201375. https:\/\/doi.org\/10.1002\/oby.22493.","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"777_CR100","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11154-025-09963-8","volume":"26","author":"M Zamboni","year":"2025","unstructured":"Zamboni M, et al. Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity. Rev Endocr Metab Disorders. 2025;26(5):767\u201383. https:\/\/doi.org\/10.1007\/s11154-025-09963-8.","journal-title":"Rev Endocr Metab Disorders"},{"issue":"8","key":"777_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13929","volume":"26","author":"S Berg","year":"2025","unstructured":"Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis. Obes Rev. 2025;26(8):e13929. https:\/\/doi.org\/10.1111\/obr.13929.","journal-title":"Obes Rev"},{"key":"777_CR102","doi-asserted-by":"publisher","unstructured":"Budini B et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine. 2026; 93.https:\/\/doi.org\/10.1016\/j.eclinm.2026.103796","DOI":"10.1016\/j.eclinm.2026.103796"},{"issue":"3","key":"777_CR103","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/dom.15400","volume":"26","author":"T Yates","year":"2024","unstructured":"Yates T, et al. Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: a prospective cohort analysis. Diabetes Obes Metab. 2024;26(3):1008\u201315. https:\/\/doi.org\/10.1111\/dom.15400.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"777_CR104","doi-asserted-by":"publisher","first-page":"e2431805","DOI":"10.2214\/ajr.24.31805","volume":"223","author":"LW Nelson","year":"2024","unstructured":"Nelson LW, et al. Intrapatient changes in CT-Based body composition after initiation of semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) therapy. AJR Am J Roentgenol. 2024;223(6):e2431805. https:\/\/doi.org\/10.2214\/ajr.24.31805.","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"777_CR105","doi-asserted-by":"publisher","first-page":"237","DOI":"10.22543\/2392-7674.1419","volume":"10","author":"Y Karaa\u011fa\u00e7","year":"2023","unstructured":"Karaa\u011fa\u00e7 Y. Sarcopenic obesity, pathogenesis, and treatment with a focus on exercise and protein intake. J Mind Med Sci. 2023;10(2):237\u201346.","journal-title":"J Mind Med Sci"},{"issue":"5","key":"777_CR106","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1139\/apnm-2015-0550","volume":"41","author":"SM Phillips","year":"2016","unstructured":"Phillips SM, Chevalier S, Leidy HJ. Protein \u201crequirements\u201d beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab. 2016;41(5):565\u201372. https:\/\/doi.org\/10.1139\/apnm-2015-0550.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"1","key":"777_CR107","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clnu.2018.05.024","volume":"38","author":"D Volkert","year":"2019","unstructured":"Volkert D, et al. ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr. 2019;38(1):10\u201347. https:\/\/doi.org\/10.1016\/j.clnu.2018.05.024.","journal-title":"Clin Nutr"},{"key":"777_CR108","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.nutres.2022.02.002","volume":"101","author":"H \u015eim\u015fek","year":"2022","unstructured":"\u015eim\u015fek H, U\u00e7ar A. Nutritional status and quality of life are associated with risk of sarcopenia in nursing home residents: a cross-sectional study. Nutr Res. 2022;101:14\u201322. https:\/\/doi.org\/10.1016\/j.nutres.2022.02.002.","journal-title":"Nutr Res"},{"key":"777_CR109","doi-asserted-by":"publisher","unstructured":"Christensen S, et al. Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: A narrative review and discussion of research needs. Obesity Pillars. 2024;11:100121. https:\/\/doi.org\/10.1016\/j.obpill.2024.100121.","DOI":"10.1016\/j.obpill.2024.100121"},{"issue":"8","key":"777_CR110","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/dom.15113","volume":"25","author":"HJ Silver","year":"2023","unstructured":"Silver HJ, et al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023;25(8):2340\u201350. https:\/\/doi.org\/10.1111\/dom.15113.","journal-title":"Diabetes Obes Metab"},{"key":"777_CR111","doi-asserted-by":"publisher","unstructured":"Johnson B, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr. 2025;12:1566498. https:\/\/doi.org\/10.3389\/fnut.2025.1566498.","DOI":"10.3389\/fnut.2025.1566498"},{"key":"777_CR112","doi-asserted-by":"publisher","unstructured":"Sandsdal RM, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41. https:\/\/doi.org\/10.1186\/s12933-023-01765-z.","DOI":"10.1186\/s12933-023-01765-z"}],"container-title":["Current Nutrition Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13668-026-00777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13668-026-00777-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13668-026-00777-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:56:54Z","timestamp":1781661414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13668-026-00777-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s13668-026-00777-x","relation":{},"ISSN":["2161-3311"],"issn-type":[{"value":"2161-3311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human or\u00a0animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"55"}}